Preventing Disused Bone Loss through Inhibition of Advanced Glycation End Products

被引:4
|
作者
Liu, Cong-Jin [1 ]
Yang, Xiao [1 ]
Wang, Shou-Hui [1 ]
Wu, Xin-Tong [1 ]
Mao, Yan [1 ]
Shi, Jing-Wen [1 ]
Fan, Yu-Bo [1 ]
Sun, Lian-Wen [1 ]
机构
[1] Beihang Univ, Beijing Adv Innovat Ctr Biomed Engn, Sch Biol Sci & Med Engn, Key Lab Biomech & Mechanobiol,Minist Educ, Beijing 100083, Peoples R China
基金
中国国家自然科学基金;
关键词
simulated microgravity; bone loss; advanced glycation end products; irbesartan; COLLAGEN CROSS-LINKS; NONENZYMATIC GLYCATION; SERUM PENTOSIDINE; AGES; SPACEFLIGHT; SUPPRESSES; MECHANISMS; RESORPTION; SCLEROSTIN; QUALITY;
D O I
10.3390/ijms24054953
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Bone loss occurs in astronauts during long-term space flight, but the mechanisms are still unclear. We previously showed that advanced glycation end products (AGEs) were involved in microgravity-induced osteoporosis. Here, we investigated the improvement effects of blocking AGEs formation on microgravity-induced bone loss by using the AGEs formation inhibitor, irbesartan. To achieve this objective, we used a tail-suspended (TS) rat model to simulate microgravity and treated the TS rats with 50 mg/kg/day irbesartan, as well as the fluorochrome biomarkers injected into rats to label dynamic bone formation. To assess the accumulation of AGEs, pentosidine (PEN), non-enzymatic cross-links (NE-xLR), and fluorescent AGEs (fAGEs) were identified in the bone; 8-hydroxydeoxyguanosine (8-OHdG) was analyzed for the reactive oxygen species (ROS) level in the bone. Meanwhile, bone mechanical properties, bone microstructure, and dynamic bone histomorphometry were tested for bone quality assessment, and Osterix and TRAP were immunofluorescences stained for the activities of osteoblastic and osteoclastic cells. Results showed AGEs increased significantly and 8-OHdG expression in bone showed an upward trend in TS rat hindlimbs. The bone quality (bone microstructure and mechanical properties) and bone formation process (dynamic bone formation and osteoblastic cells activities) were inhibited after tail-suspension, and showed a correlation with AGEs, suggesting the elevated AGEs contributed to the disused bone loss. After being treated with irbesartan, the increased AGEs and 8-OHdG expression were significantly inhibited, suggesting irbesartan may reduce ROS to inhibit dicarbonyl compounds, thus suppressing AGEs production after tail-suspension. The inhibition of AGEs can partially alter the bone remodeling process and improve bone quality. Both AGEs accumulation and bone alterations almost occurred in trabecular bone but not in cortical bone, suggesting AGEs effects on bone remodeling under microgravity are dependent on the biological milieu.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Effects of advanced glycation end products on osteocytes mechanosensitivity
    Yang, Xiao
    Liu, Cong-Jin
    Wang, Zhen-Zhen
    Ding, Dong
    Shi, Jing-Wen
    Wu, Xin-Tong
    Sun, Lian-Wen
    Fan, Yu-Bo
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2021, 568 : 151 - 157
  • [32] Citral: A potent inhibitor of advanced glycation end products
    Yang, Xin
    Wei, Siyu
    Hou, Kangdi
    Wei, Yumeng
    Lin, Mengyi
    Hu, Xiaosong
    Chen, Fang
    Zhu, Yuchen
    FOOD CHEMISTRY, 2025, 463
  • [33] Advanced glycation end products in musculoskeletal system and disorders
    Suzuki, Akinobu
    Yabu, Akito
    Nakamura, Hiroaki
    METHODS, 2022, 203 : 179 - 186
  • [34] Advanced glycation end products as a biomarker for incisional hernia
    J. J. Harlaar
    H. H. Eker
    K. A. Vakalopoulos
    M. C. Cabezas
    A. C. van der Ham
    W. W. Vrijland
    J. Jeekel
    J. F. Lange
    Hernia, 2017, 21 : 537 - 541
  • [35] Effects of advanced glycation end products on stem cell
    Zheng, Zetai
    Zhou, Hui
    Zhang, Wenwen
    Wang, Tingyu
    Swamiappan, Sathiskumar
    Peng, Xinsheng
    Zhou, Yanfang
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
  • [36] Advanced glycation end products as a biomarker for incisional hernia
    Harlaar, J. J.
    Eker, H. H.
    Vakalopoulos, K. A.
    Cabezas, M. C.
    van der Ham, A. C.
    Vrijland, W. W.
    Jeekel, J.
    Lange, J. F.
    HERNIA, 2017, 21 (04) : 537 - 541
  • [37] Association of advanced glycation end products in Dupuytren disease
    Takase, Fumiaki
    Mifune, Yutaka
    Inui, Atsuyuki
    Ueda, Yasuhiro
    Kataoka, Takeshi
    Kokubu, Takeshi
    Kuroda, Ryosuke
    JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH, 2018, 13
  • [38] Causative or associative: A critical review of the role of advanced glycation end-products in bone fragility
    Willett, Thomas L.
    Voziyan, Paul
    Nyman, Jeffry S.
    BONE, 2022, 163
  • [39] Advanced glycation end products and schizophrenia: A systematic review
    Kouidrat, Youssef
    Amad, Ali
    Arai, Makoto
    Miyashita, Mitsuhiro
    Lalau, Jean-Daniel
    Loas, Gwenole
    Itokawa, Masanari
    JOURNAL OF PSYCHIATRIC RESEARCH, 2015, 66-67 : 112 - 117
  • [40] Advanced glycation end products biphasically modulate bone resorption in osteoclast-like cells
    Li, Ziqing
    Li, Chaohong
    Zhou, Yuhuan
    Chen, Weishen
    Luo, Guotian
    Zhang, Ziji
    Wang, Haixing
    Zhang, Yangchun
    Xu, Dongliang
    Sheng, Puyi
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2016, 310 (05): : E355 - E366